e6vk
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of October 2007
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home
country exchange on which the registrant’s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant’s security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| |
|
|
|
|
| |
|
Oncolytics
Biotech Inc.
(Registrant) |
| |
| |
|
|
|
|
| |
| Date: October 24, 2007 |
|
By: |
|
/s/ Doug Ball
Doug Ball
Chief Financial Officer |
 |
210, 1167 Kensington Crescent N.W.
Calgary, Alberta
Canada T2N 1X7 |
FOR IMMEDIATE RELEASE
Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results
of U.K. Phase Ia/Ib Combination REOLYSIN® and Radiation Clinical Trial
CALGARY, AB, — October 24, 2007 – Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY)
today announced that a poster presentation covering interim results from a U.K. Phase Ia/Ib
combination REOLYSIN®/radiation clinical trial for patients with advanced or metastatic
cancers is scheduled to be presented today at the AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics in San Francisco. The conference runs from October 22-26,
2007.
“We are very encouraged with the results of this trial to date,” said Dr. Brad Thompson, President
and CEO of Oncolytics. “The data is supportive of our ongoing Phase II
REOLYSIN®/radiation cotherapy trial in the U.K.”
The interim results of the Ia/Ib trial demonstrate that intratumoural treatment with
REOLYSIN® and radiation is well tolerated and results in both local and remote
anti-tumour activity in patients with a variety of advanced cancers. Oncolytics continues to
enroll patients in the Ib portion of this trial, and is also actively enrolling patients in a Phase
II trial examining this treatment combination.
The presentation, entitled “A Phase I study to evaluate the feasibility, safety and biological
effects of intratumoural administration of wild-type Reovirus (REOLYSIN®) in combination
with radiation in patients with advanced malignancies” will be delivered by Dr. Dean Harris of The
Institute of Cancer Research, London.
These interim results were also presented in early October at the National Cancer Research
Institute (NCRI) Cancer Conference in Birmingham, U.K.
The poster presentation will be posted on the Oncolytics website today at
www.oncolyticsbiotech.com.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I and
Phase II human trials using REOLYSIN®, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com
About The Institute of Cancer Research
The Institute of Cancer Research is Europe’s leading cancer research centre with expert scientists
working on cutting edge research. It was founded in 1909 to carry out research into the causes of
cancer and to develop new strategies for its prevention, diagnosis, treatment and care. Website
at: www.icr.ac.uk
The Institute works in a unique partnership with The Royal Marsden NHS Foundation Trust, forming
the largest comprehensive cancer centre in Europe. This relationship enables close daily contact
between research scientists and those on the frontline in the fight against cancer — the
clinicians, the carers and most importantly, the patients.
This press release contains forward-looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
Company’s expectations related to the Phase Ia/Ib U.K. combination REOLYSIN® and
radiation clinical trial, and the Company’s belief as to the potential of REOLYSIN® as a
cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the
Company’s actual results to differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of funds and resources to pursue
research and development projects, the efficacy of REOLYSIN® as a cancer treatment, the
success and timely completion of clinical studies and trials, the Company’s ability to successfully
commercialize REOLYSIN®, uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the
Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for
additional information on risks and uncertainties relating to the forward-looking statements.
Investors are cautioned against placing undue reliance on forward-looking statements. The Company
does not undertake to update these forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
| |
|
|
|
|
| Oncolytics Biotech Inc. |
|
The Equicom Group |
|
The Investor Relations Group |
| Cathy Ward |
|
Nick Hurst |
|
Erika Moran |
| 210, 1167 Kensington Cr NW |
|
325, 300
5th Ave. SW |
|
11 Stone Street, 3rd Floor |
| Calgary, Alberta T2N 1X7 |
|
Calgary, Alberta T2P 3C4 |
|
New York, NY 10004 |
| Tel: 403.670.7377 |
|
Tel: 403.538.4845 |
|
Tel: 212.825.3210 |
| Fax: 403.283.0858 |
|
Fax: 403.237-6916 |
|
Fax: 212.825.3229 |
| cathy.ward@oncolytics.ca |
|
nhurst@equicomgroup.com |
|
emoran@investorrelationsgroup.com |
-30-